Toripalimab resistance

Toripalimab (Toripalimab) is an immune checkpoint inhibitor commonly used to treat certain malignant tumors, such as advanced or metastatic cutaneous melanoma, metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and advanced or metastatic urothelial carcinoma (UC). However, drug resistance is a challenge that may arise.

Resistance is a condition in which a patient's response to toripalimab treatment gradually decreases or fails completely. The occurrence of drug resistance may be related to multiple factors, including changes within tumor cells or the tumor microenvironment. During treatment with toripalimab, tumor cells may undergo certain gene mutations or abnormal expression, causing the immune system to be unable to effectively recognize and attack these cells. In addition, immunosuppressive factors in the tumor microenvironment may also increase, counteracting the therapeutic effect of toripalimab.

To overcome resistance to toripalimab, researchers are working to find new combination treatment regimens or strategies. Choose the most appropriate treatment option based on the patient's genotype and tumor characteristics. For example, genetic testing is used to determine the presence of cancer lesions to decide whether to continue treatment with toripalimab. Drugs are changed regularly during treatment to prevent tumors from developing resistance to specific drugs. For example, combination with other immunotherapy drugs (such as other antiPD-1 antibodies, anti-CTLA-4 antibodies) may improve the therapeutic effect of toripalimab. In addition, some studies have also explored the combined application with other treatment modalities such as chemotherapy, radiotherapy, and targeted therapy. However, everyone’s physique is different and their resistance to drugs is also different. If drug resistance occurs after using the drug, please inform your doctor in time and do not adjust the drug dosage yourself.